Life Science Investing MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
Life Science Investing MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
